Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in Refractory Lupus Nephritis (KYSA-3)
2024-513329-22-00Phase 2Completed
- Sponsor
- Kyverna Therapeutics
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivocabtagene autoleucel in refractory lupus nephritis (RLN), sponsored by Kyverna Therapeutics. Started Jun 2024; status: completed.
02
Drugs
mivocabtagene autoleucel
03
Conditions
refractory lupus nephritis (RLN)
Beyond the preview
Go deeper on 2024-513329-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513329-22-00.